Last reviewed · How we verify
Germline BRCA-mutated, HER2-negative metastatic breast cancer
Approved treatments
- Talzenna · Pfizer
Talazoparib inhibits PARP enzymes, causing DNA damage and cell death in cancer cells with DNA repair defects. - Tecentriq · Roche
Tecentriq works by blocking a protein called PD-L1, which helps cancer cells hide from the immune system. - Piqray · Novartis
Alpelisib inhibits PI3Kα, blocking Akt-signaling and preventing tumor growth and organ abnormalities in PROS disorders. - Talzenna · Pfizer
Talzenna blocks PARP enzymes, which are involved in DNA repair, to prevent cancer cell growth.
Clinical guidelines
- FDA label — any
TALZENNA is indicated as a single agent for the treatment of adult patients with deleterious or suspected deleterious germline breast cancer susceptibility gene (BRCA)-mutated (gBRCAm) human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Germline BRCA-mutated, HER2-negative metastatic breast cancer patent landscape — cliff calendar, originator estates, attackable patents
- Germline BRCA-mutated, HER2-negative metastatic breast cancer treatment landscape brief
- Germline BRCA-mutated, HER2-negative metastatic breast cancer treatment updates RSS
Frequently asked questions about Germline BRCA-mutated, HER2-negative metastatic breast cancer
What drugs treat Germline BRCA-mutated, HER2-negative metastatic breast cancer?
Tracked treatments include Talzenna, Tecentriq, Piqray.
What is the treatment for Germline BRCA-mutated, HER2-negative metastatic breast cancer?
Standard treatment for Germline BRCA-mutated, HER2-negative metastatic breast cancer includes Talzenna, Tecentriq, Piqray. See the treatment landscape page for first-line, second-line and salvage options.
What are the treatment guidelines for Germline BRCA-mutated, HER2-negative metastatic breast cancer?
FDA label publishes guidelines for Germline BRCA-mutated, HER2-negative metastatic breast cancer. 1 guideline references tracked.
Related
- Treatment landscape: Germline BRCA-mutated, HER2-negative metastatic breast cancer patent cliff · Germline BRCA-mutated, HER2-negative metastatic breast cancer CI report
- Treatment: Talzenna · Pfizer
- Treatment: Tecentriq · Roche
- Treatment: Piqray · Novartis
- Treatment: Talzenna · Pfizer
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing